Different perspectives and educational resources

Educational resources about unmet needs in later lines of CML

Patient Stories

When thinking of CML, some may think of early-line success
Hear from patients living with later lines of CML

Expert Perspectives

Additional Resources

Unmet need

  • Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood. 2009;114(10):2168-2171.
  • Ibrahim AR, Paliompeis C, Bua M, et al. Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010;116(25):5497-5500.

Off-target activities

  • Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule–kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336.
  • Karaman MW, Herrgard H, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26(1):127-132.
  • Huang D, Zhou T, Lafleur K, Nevado C, et al. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics. 2010;26(2):198-204.

Mechanism of action

  • Fallacara AL, Tintori C, Radi M, et al. Insight into the allosteric inhibition of Abl kinase. J Chem Inf Model. 2014;54(5):1325-1338.

CML, chronic myeloid leukemia; TKI, tyrosine kinase inhibitor.

This site is for US health care professionals only.

Use of website is governed by the Terms of Use and Privacy Policy

Copyright © 2021 Novartis Pharmaceuticals Corporation. All rights reserved.

 

9/21 152562